Hematology
Conditions
Brief summary
To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.
Interventions
Naproxen sodium 220 mg qd or bid
ASA 81 mg qd
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy, ambulatory, male and female volunteers between 18 - 70 years of age with a Body Mass Index (BMI) of approximately 18 to 30 kg/m2, and a total body weight \> 50 kg (110 lbs) * Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®, or a double barrier and have a negative pregnancy test at Screening and immediately prior to investigational product administration on Day 1 and Day 6. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy * Results of screening and clinical laboratory tests are within normal range or considered not clinically significant by the Principal Investigator and the Sponsor * Be willing and able to participate in all scheduled visits, treatment plan, laboratory tests and other trial procedures according to the protocol * Provide a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the trial.
Exclusion criteria
* History of hypersensitivity or asthma type symptoms with use of aspirin, naproxen sodium and similar pharmacological agents or components of the products * Females who are pregnant or lactating * Any disorder of the Aspirin Triad Syndrome (i.e., asthma, rhinitis or nasal polyps), or have chronic urticaria * Eighteen to twenty years old with a viral infection, with or without fever within one month prior to start of Run-in Period * History of gastrointestinal bleeding or perforation, related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding) * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, infectious diseases or malignancies * Any abnormal laboratory value or physical finding that according to the Investigator that may interfere with the interpretation of the study results or be indicative of an underlying disease state * Have taken any medications including NSAIDs (except acceptable forms of birth control) within 7 days prior to the start of the Run-in Period or throughout the study, unless in the opinion of the Investigator and the Sponsor, the medication will not interfere with the study procedures, data integrity, data interpretation or compromise the safety of the subject * Have taken antiplatelet or anticoagulant drugs within 30 days prior to start of the Run-in Period or during their participation in the study * Have donated blood or blood components within 30 days prior to study entry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration | At hour 24 on Day 16 post treatment | Inhibition of serum TXB2 at specified time point was calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% Confidence Interval (CI) were calculated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19 (except 24 hours on Day 16) | Inhibition of serum TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated. |
| Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19 | Inhibition of AA-induced platelet aggregation at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated. The platelet aggregation change-from-baseline scores range broadly in large part due to inclusion of participants with low baseline platelet aggregation scores. |
| Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19 | Inhibition of plasma TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated. |
Countries
United States
Participant flow
Recruitment details
The study was conducted at a single site in United States between 16-Feb-2015 (first patient first visit) and 08-May-2015 (last patient last visit).
Pre-assignment details
Of 117 screened participants in Run-In period, 15 were not randomized into Treatment Period. 2 participants were not randomized because of non-compliance; 3 because of investigator's decision; the other 10 because of other reasons (e.g arachidonic acid-induced platelet aggregation≥20% or pre-randomization elimination of back-up participants).
Participants by arm
| Arm | Count |
|---|---|
| Group 1-IR ASA Co-administered With Naproxen Sodium Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed. | 17 |
| Group 2-IR ASA 30 Min After Naproxen Sodium Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed. | 17 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed. | 17 |
| Group 4-IR ASA Only Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed. | 17 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed. | 17 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed. | 17 |
| Non-Randomized Fifteen participants were not randomized into Treatment Period. | 15 |
| Total | 117 |
Baseline characteristics
| Characteristic | Total | Group 1-IR ASA Co-administered With Naproxen Sodium | Group 2-IR ASA 30 Min After Naproxen Sodium | Group 3-IR ASA 8 Hours After Naproxen Sodium | Group 4-IR ASA Only | Group 5-IR ASA 30 Min Before Naproxen Sodium | Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Non-Randomized |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 37.1 years STANDARD_DEVIATION 11 | 41.3 years STANDARD_DEVIATION 8.46 | 31.2 years STANDARD_DEVIATION 7.19 | 37.5 years STANDARD_DEVIATION 13.41 | 34.2 years STANDARD_DEVIATION 8.76 | 38.8 years STANDARD_DEVIATION 12.09 | 38.9 years STANDARD_DEVIATION 10.62 | 38.2 years STANDARD_DEVIATION 13.74 |
| Sex: Female, Male Female | 36 Participants | 7 Participants | 4 Participants | 6 Participants | 4 Participants | 4 Participants | 7 Participants | 4 Participants |
| Sex: Female, Male Male | 81 Participants | 10 Participants | 13 Participants | 11 Participants | 13 Participants | 13 Participants | 10 Participants | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 102 | 4 / 17 | 1 / 17 | 4 / 17 | 3 / 17 | 2 / 17 | 4 / 17 |
| serious Total, serious adverse events | 0 / 102 | 0 / 17 | 0 / 17 | 0 / 17 | 0 / 17 | 0 / 17 | 0 / 17 |
Outcome results
Primary
Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration
Inhibition of serum TXB2 at specified time point was calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% Confidence Interval (CI) were calculated.
Time frame: At hour 24 on Day 16 post treatment
Population: Percentages are based on the number of participants in the Evaluable Population in each treatment group.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration | 93.09 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration | 87.71 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration | 92.87 percentage |
| Group 4-IR ASA Only | Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration | 98.72 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration | 95.35 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration | 95.65 percentage |
Secondary
Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration
Inhibition of AA-induced platelet aggregation at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated. The platelet aggregation change-from-baseline scores range broadly in large part due to inclusion of participants with low baseline platelet aggregation scores.
Time frame: At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19
Population: Percentages are based on the number of participants in the Evaluable Population in each treatment group. Evaluable participants number in Group 4 at time point Day 7/1 Hour was 12; 11 in group 6, 7 in Group 5, 12 in Group 6 at Day 16/1 Hour.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 68.96 percentage | 95% Confidence Interval 39.662 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | -121.76 percentage | 95% Confidence Interval 630.765 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 61.74 percentage | 95% Confidence Interval 63.4 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 36.41 percentage | 95% Confidence Interval 162.35 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 62.36 percentage | 95% Confidence Interval 68.382 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 80.60 percentage | 95% Confidence Interval 26.517 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 58.60 percentage | 95% Confidence Interval 58.893 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 75.25 percentage | 95% Confidence Interval 42.568 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 74.45 percentage | 95% Confidence Interval 42.678 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 79.88 percentage | 95% Confidence Interval 26.425 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 73.86 percentage | 95% Confidence Interval 36.769 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 67.47 percentage | 95% Confidence Interval 37.467 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 76.23 percentage | 95% Confidence Interval 30.966 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 78.48 percentage | 95% Confidence Interval 27.969 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 76.46 percentage | 95% Confidence Interval 36.017 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 83.17 percentage | 95% Confidence Interval 20.398 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 82.30 percentage | 95% Confidence Interval 22.57 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 78.66 percentage | 95% Confidence Interval 36.988 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 64.06 percentage | 95% Confidence Interval 64.304 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 69.18 percentage | 95% Confidence Interval 58.761 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 60.96 percentage | 95% Confidence Interval 72.629 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 1.08 percentage | 95% Confidence Interval 313.927 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 69.69 percentage | 95% Confidence Interval 57.918 |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 89.86 percentage | 95% Confidence Interval 13.568 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 25.27 percentage | 95% Confidence Interval 119.755 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 56.77 percentage | 95% Confidence Interval 63.792 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 1.70 percentage | 95% Confidence Interval 168.415 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 86.40 percentage | 95% Confidence Interval 17.991 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 74.55 percentage | 95% Confidence Interval 46.13 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 46.16 percentage | 95% Confidence Interval 79.122 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 69.16 percentage | 95% Confidence Interval 43.503 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 24.15 percentage | 95% Confidence Interval 114.782 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 12.86 percentage | 95% Confidence Interval 144.823 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 33.43 percentage | 95% Confidence Interval 110.105 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 51.22 percentage | 95% Confidence Interval 74.825 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 28.54 percentage | 95% Confidence Interval 113.063 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 50.21 percentage | 95% Confidence Interval 77.242 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 61.20 percentage | 95% Confidence Interval 63.333 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 12.78 percentage | 95% Confidence Interval 139.818 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 70.98 percentage | 95% Confidence Interval 51.499 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 46.31 percentage | 95% Confidence Interval 91.924 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 48.51 percentage | 95% Confidence Interval 73.341 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 80.90 percentage | 95% Confidence Interval 28.329 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 74.07 percentage | 95% Confidence Interval 40.473 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 41.10 percentage | 95% Confidence Interval 103.816 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 70.84 percentage | 95% Confidence Interval 46.622 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 64.26 percentage | 95% Confidence Interval 51.05 |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 68.65 percentage | 95% Confidence Interval 45.824 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 36.92 percentage | 95% Confidence Interval 204.36 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 31.96 percentage | 95% Confidence Interval 178.297 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | -452.48 percentage | 95% Confidence Interval 2088.027 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 62.32 percentage | 95% Confidence Interval 100.84 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | -3.29 percentage | 95% Confidence Interval 331.881 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 37.52 percentage | 95% Confidence Interval 204.341 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 35.43 percentage | 95% Confidence Interval 204.054 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 29.02 percentage | 95% Confidence Interval 230.055 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 21.74 percentage | 95% Confidence Interval 255.742 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 51.59 percentage | 95% Confidence Interval 126.753 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 23.64 percentage | 95% Confidence Interval 228.479 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 15.41 percentage | 95% Confidence Interval 281.253 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | -24.72 percentage | 95% Confidence Interval 408.994 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 41.29 percentage | 95% Confidence Interval 178.089 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 29.25 percentage | 95% Confidence Interval 229.744 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | -17.95 percentage | 95% Confidence Interval 275.811 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 10.80 percentage | 95% Confidence Interval 280.405 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 11.16 percentage | 95% Confidence Interval 254.042 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 15.96 percentage | 95% Confidence Interval 281.846 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 53.24 percentage | 95% Confidence Interval 103.247 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 33.12 percentage | 95% Confidence Interval 203.704 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 11.96 percentage | 95% Confidence Interval 280.718 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 21.46 percentage | 95% Confidence Interval 255.47 |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 5.55 percentage | 95% Confidence Interval 306.389 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 84.45 percentage | 95% Confidence Interval 25.743 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 78.50 percentage | 95% Confidence Interval 37.671 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 89.12 percentage | 95% Confidence Interval 18.535 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 83.67 percentage | 95% Confidence Interval 34.194 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 86.12 percentage | 95% Confidence Interval 21.728 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 85.92 percentage | 95% Confidence Interval 21.762 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 81.36 percentage | 95% Confidence Interval 37.422 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 81.38 percentage | 95% Confidence Interval 31.472 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 85.19 percentage | 95% Confidence Interval 25.762 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 85.25 percentage | 95% Confidence Interval 18.848 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 83.53 percentage | 95% Confidence Interval 25.476 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 83.48 percentage | 95% Confidence Interval 25.466 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 83.48 percentage | 95% Confidence Interval 25.514 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 91.12 percentage | 95% Confidence Interval 4.541 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 86.00 percentage | 95% Confidence Interval 17.935 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 83.71 percentage | 95% Confidence Interval 25.383 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 85.43 percentage | 95% Confidence Interval 25.873 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 83.97 percentage | 95% Confidence Interval 25.386 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 81.62 percentage | 95% Confidence Interval 33.415 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 87.73 percentage | 95% Confidence Interval 8.777 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 79.16 percentage | 95% Confidence Interval 29.318 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 78.20 percentage | 95% Confidence Interval 33.051 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 82.98 percentage | 95% Confidence Interval 29.512 |
| Group 4-IR ASA Only | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 80.81 percentage | 95% Confidence Interval 33.244 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 71.93 percentage | 95% Confidence Interval 52.602 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 82.55 percentage | 95% Confidence Interval 17.893 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 44.97 percentage | 95% Confidence Interval 112.099 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 73.69 percentage | 95% Confidence Interval 31.859 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 64.14 percentage | 95% Confidence Interval 40.389 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 81.05 percentage | 95% Confidence Interval 19.743 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 83.51 percentage | 95% Confidence Interval 21.986 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 82.13 percentage | 95% Confidence Interval 29.286 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 62.67 percentage | 95% Confidence Interval 45.474 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 38.58 percentage | 95% Confidence Interval 138.715 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 75.89 percentage | 95% Confidence Interval 24.067 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 73.73 percentage | 95% Confidence Interval 32.648 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 79.51 percentage | 95% Confidence Interval 21.218 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 75.15 percentage | 95% Confidence Interval 30.948 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 70.87 percentage | 95% Confidence Interval 35.515 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 76.02 percentage | 95% Confidence Interval 26.733 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 74.61 percentage | 95% Confidence Interval 38.546 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 78.01 percentage | 95% Confidence Interval 26.265 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 77.61 percentage | 95% Confidence Interval 29.401 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 82.13 percentage | 95% Confidence Interval 19.364 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 82.63 percentage | 95% Confidence Interval 20.393 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 71.35 percentage | 95% Confidence Interval 31.709 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 82.37 percentage | 95% Confidence Interval 27.172 |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 88.43 percentage | 95% Confidence Interval 10.953 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 67.55 percentage | 95% Confidence Interval 79.461 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 51.40 percentage | 95% Confidence Interval 116.489 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 17.11 percentage | 95% Confidence Interval 249.918 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 41.51 percentage | 95% Confidence Interval 144.334 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 84.46 percentage | 95% Confidence Interval 28.685 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 13.17 percentage | 95% Confidence Interval 215.066 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 71.64 percentage | 95% Confidence Interval 52.123 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 87.02 percentage | 95% Confidence Interval 23.703 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 71.27 percentage | 95% Confidence Interval 57.042 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 26.91 percentage | 95% Confidence Interval 183.636 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 43.92 percentage | 95% Confidence Interval 157.676 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 53.04 percentage | 95% Confidence Interval 118.315 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 14.85 percentage | 95% Confidence Interval 263.93 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 81.07 percentage | 95% Confidence Interval 26.57 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 37.09 percentage | 95% Confidence Interval 170.694 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | -151.06 percentage | 95% Confidence Interval 863.434 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 30.45 percentage | 95% Confidence Interval 182.916 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 45.12 percentage | 95% Confidence Interval 141.196 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 18.99 percentage | 95% Confidence Interval 222.208 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 48.27 percentage | 95% Confidence Interval 117.511 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 33.64 percentage | 95% Confidence Interval 197.114 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 44.02 percentage | 95% Confidence Interval 157.466 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 52.03 percentage | 95% Confidence Interval 131.415 |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 58.64 percentage | 95% Confidence Interval 105.239 |
Secondary
Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration
Inhibition of serum TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.
Time frame: At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19 (except 24 hours on Day 16)
Population: Percentages are based on the number of participants in the Evaluable Population in each treatment group.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 18 hour | 89.44 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 1 hour | 99.86 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 18 hour | 97.21 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 12 hour | 97.67 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 6 hour | 98.26 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 12 hour | 92.54 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 1 hour | 95.71 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 18 hour | 94.19 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 12 hour | 96.59 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 6 hour | 97.69 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 24 hour | 89.05 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 6 hour | 93.55 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 3 hour | 98.80 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 1 hour | 99.06 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 24 hour | 99.01 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 18 hour | 99.18 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 1 hour | 98.35 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 3 hour | 95.49 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 12 hour | 99.59 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 6 hour | 99.69 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 3 hour | 99.84 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 24 hour | 97.04 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 3 hour | 98.52 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 1 hour | 99.83 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 18 hour | 87.19 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 24 hour | 83.67 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 1 hour | 97.89 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 3 hour | 97.90 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 6 hour | 97.43 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 12 hour | 96.90 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 18 hour | 96.29 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 24 hour | 96.16 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 3 hour | 99.79 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 6 hour | 99.67 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 12 hour | 99.48 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 18 hour | 99.18 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 24 hour | 99.55 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 1 hour | 98.38 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 3 hour | 97.67 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 6 hour | 96.26 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 12 hour | 92.71 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 18 hour | 92.23 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 1 hour | 94.63 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 3 hour | 92.79 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 6 hour | 90.91 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 12 hour | 91.15 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 1 hour | 98.89 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 24 hour | 90.39 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 12 hour | 99.12 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 3 hour | 99.54 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 18 hour | 98.52 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 18 hour | 95.68 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 6 hour | 98.98 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 1 hour | 99.69 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 18 hour | 99.76 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 12 hour | 94.13 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 12 hour | 96.31 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 6 hour | 95.64 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 6 hour | 97.40 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 1 hour | 95.56 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 24 hour | 97.78 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 3 hour | 96.43 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 6 hour | 99.44 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 18 hour | 94.23 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 3 hour | 98.02 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 24 hour | 97.98 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 1 hour | 98.32 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 3 hour | 99.05 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 12 hour | 98.77 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 12 hour | 99.30 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 3 hour | 99.68 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 18 hour | 98.95 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 6 hour | 99.55 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 3 hour | 99.66 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 12 hour | 99.42 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 18 hour | 98.88 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 6 hour | 99.52 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 12 hour | 99.26 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 1 hour | 99.69 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 6 hour | 99.48 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 3 hour | 99.68 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 12 hour | 99.31 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 6 hour | 99.50 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 18 hour | 98.86 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 1 hour | 99.67 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 1 hour | 99.70 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 24 hour | 98.49 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 24 hour | 98.71 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 3 hour | 99.64 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 24 hour | 98.70 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 1 hour | 99.71 percentage |
| Group 4-IR ASA Only | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 18 hour | 99.01 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 18 hour | 96.45 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 24 hour | 96.01 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 1 hour | 99.91 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 1 hour | 98.16 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 3 hour | 99.86 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 6 hour | 99.75 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 12 hour | 99.68 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 3 hour | 96.96 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 18 hour | 99.39 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 24 hour | 91.40 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 24 hour | 99.23 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 12 hour | 94.74 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 1 hour | 99.28 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 3 hour | 99.19 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 6 hour | 98.43 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 18 hour | 93.42 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 12 hour | 97.84 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 6 hour | 95.31 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 6 hour | 97.84 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 3 hour | 98.27 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 1 hour | 97.42 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 12 hour | 97.33 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 18 hour | 96.62 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 12 hour | 92.60 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 18 hour | 97.73 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 24 hour | 99.80 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 6 hour | 93.91 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 3 hour | 95.92 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 3 hour | 94.44 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 18 hour | 99.70 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 24 hour | 84.27 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 12 hour | 99.63 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 1 hour | 96.95 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 6 hour | 93.25 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 1 hour | 94.06 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 24 hour | 90.67 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 6 hour | 99.70 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 3 hour | 99.80 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 18 hour | 90.94 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 6 hour | 97.51 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 19 at 12 hour | 92.00 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 12 hour | 95.38 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 17 at 18 hour | 88.14 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 7 at 1 hour | 99.84 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 3 hour | 98.53 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration | Day 16 at 1 hour | 98.81 percentage |
Secondary
Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration
Inhibition of plasma TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.
Time frame: At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19
Population: Percentages are based on the number of participants in the Evaluable Population in each treatment group. Evaluable participants number in Group 1 at time point Day 7/1 Hour, Day 7/3 Hour, Day 7/6 Hour, Day 7/12 Hour was 12.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 98.06 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 97.82 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 97.95 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 97.75 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 97.85 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 96.62 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 98.84 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 93.03 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 93.55 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 89.55 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 86.61 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 86.42 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 86.19 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 85.45 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 82.90 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 83.49 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 85.77 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 79.55 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 92.68 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 91.03 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 90.57 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 91.59 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 91.20 percentage |
| Group 1-IR ASA Co-administered With Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 93.76 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 96.09 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 79.99 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 98.57 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 81.22 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 93.50 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 90.16 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 84.77 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 95.49 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 98.25 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 89.25 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 89.25 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 97.92 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 91.49 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 88.62 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 98.82 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 85.63 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 98.26 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 92.04 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 90.93 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 84.41 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 89.65 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 79.06 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 72.66 percentage |
| Group 2-IR ASA 30 Min After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 78.34 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 95.18 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 86.53 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 86.14 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 90.40 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 98.37 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 83.08 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 82.14 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 93.66 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 92.60 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 92.35 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 93.68 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 94.85 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 86.50 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 98.89 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 89.55 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 96.66 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 97.72 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 88.76 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 77.71 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 75.67 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 92.62 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 98.79 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 95.32 percentage |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 97.59 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 96.91 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 96.29 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 95.04 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 96.63 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 98.99 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 97.37 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 98.50 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 97.42 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 95.69 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 95.78 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 98.72 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 98.01 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 97.34 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 96.24 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 97.46 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 95.47 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 97.23 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 98.05 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 97.82 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 98.34 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 97.61 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 97.29 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 98.24 percentage |
| Group 4-IR ASA Only | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 97.49 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 93.28 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 95.56 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 92.84 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 99.06 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 99.40 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 94.39 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 96.17 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 92.07 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 96.73 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 97.97 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 98.95 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 88.49 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 92.30 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 88.52 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 93.72 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 98.54 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 92.39 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 94.53 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 98.13 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 93.75 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 96.14 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 85.70 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 92.42 percentage |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 92.74 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 12 hour | 82.13 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 24 hour | 86.87 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 12 hour | 98.36 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 18 hour | 70.90 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 18 hour | 85.67 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 12 hour | 80.66 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 18 hour | 91.03 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 24 hour | 81.34 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 24 hour | 81.67 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 6 hour | 97.93 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 1 hour | 79.36 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 12 hour | 89.45 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 3 hour | 79.82 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 6 hour | 91.27 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 3 hour | 90.62 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 18 hour | 97.87 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 1 hour | 98.67 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 16 at 1 hour | 94.95 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 3 hour | 97.68 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 3 hour | 83.94 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 1 hour | 90.00 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 7 at 24 hour | 98.44 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 17 at 6 hour | 85.82 percentage |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration | Day 19 at 6 hour | 81.14 percentage |